Download presentation
Presentation is loading. Please wait.
Published byΟλυμπία Γιαννόπουλος Modified over 6 years ago
2
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
3
ARIC PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk
7
PCSK9-Directed Therapies in Development
8
Effects of Evolocumab (AMG-145) on LDL-C Levels Phase 1b Study Design
9
Evolocumab -- Phase 1b Change in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy
10
PCSK9 Inhibitors Phase 2
11
MENDEL Evolocumab Phase 2 Monotherapy in Patients With Hypercholesterolemia
12
MENDEL Study Design
13
MENDEL Evolocumab Monotherapy for Hypercholesterolemia
14
PCSK9 Inhibitors Phase 2
15
Alirocumab (SAR236553) Add-on to Atorvastatin
16
Alirocumab Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin
17
Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia
18
LAPLACE-TIMI 57 Evolocumab in Combination With Statin in Patients With Hypercholesterolemia
19
LAPLACE-TIMI 57 Study Design
20
LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in LDL-C From Baseline
21
Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Phase 2 Studies
22
Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy Doses Studied
23
Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Pooled Results
24
PCSK9 Inhibitors Phase 2
25
GAUSS Phase 2 Evolocumab in Statin-Intolerant Patients
26
GAUSS Evolocumab in Statin Intolerance
27
PCSK9 Inhibitors Phase 2
28
Effect of Alirocumab on LDL-C in Heterozygous FH
29
RUTHERFORD Phase 2 Evolocumab in Patients With Heterozygous FH
30
RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH
31
Phase 3 Trials
32
OSLER Phase 3 Extension Study
33
OSLER Effect of Evolocumab on LDL-C after 52 Weeks
34
ODYSSEY Outcomes Phase 3 Post-ACS With Alirocumab
38
References
39
References (cont)
40
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.